Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange Detected- Added a government funding notice with operational details and links; - Updated version to v3.2.0; - Removed reference to v3.1.0.SummaryDifference3%
- Check17 days agoChange DetectedUpdate indicates a new software release (v3.1.0) replacing the previous v3.0.2—no other substantive content changes are shown.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed.SummaryDifference0.2%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location in Petah Tikva, Israel, while also removing various related terms and resources, including previous mentions of pembrolizumab and other medical classifications.SummaryDifference2%
- Check60 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.